Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".

Stephane BorentainPooja DesaiDong-Jing FuLi Nancy ChenRosanne LaneMaju MathewsCarla M Canuso

Published in: Journal of psychopharmacology (Oxford, England) (2022)

Esketamine improves response, remission, and depressive symptoms as early as 24 h post-first dose among patients with TRD and among patients with MDD and active suicidal ideation with intent.

Keyphrases

major depressive disorder
depressive symptoms
bipolar disorder
social support
sleep quality
small molecule
pain management
disease activity
ulcerative colitis
systemic lupus erythematosus